BRIEF-Pfizer Says Lorbrena Shows 55% Likelihood Of Progression-Free Survival At 7 Years In NSCLC Trial

Pfizer Inc.

Pfizer Inc.

PFE

0.00

May 29 (Reuters) - Pfizer Inc PFE.N:

  • ANNOUNCES SEVEN-YEAR RESULTS FROM CROWN TRIAL OF LORBRENA IN ADVANCED NSCLC

  • LORBRENA SHOWS 55% LIKELIHOOD OF PROGRESSION-FREE SURVIVAL AT 7 YEARS IN NSCLC TRIAL

  • LORBRENA MEDIAN PROGRESSION-FREE SURVIVAL NOT REACHED AT 7-YEAR FOLLOW-UP

Source text: ID:nBwcgmnK2a

Further company coverage: PFE.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.